Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
Immune checkpoints, such as programmed death-ligand 1 (PD-L1), limit T-cell function and tumor cells use this ligand to escape the anti-tumor immune response. Treatments with monoclonal antibodies blocking these checkpoints have shown long-lasting responses, but only in a subset of patients. This st...
Main Authors: | Jessica Bridoux, Katrijn Broos, Quentin Lecocq, Pieterjan Debie, Charlotte Martin, Steven Ballet, Geert Raes, Sara Neyt, Christian Vanhove, Karine Breckpot, Nick Devoogdt, Vicky Caveliers, Marleen Keyaerts, Catarina Xavier |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/10/1388 |
Similar Items
-
Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry
by: Dora Mugoli Chigoho, et al.
Published: (2021-06-01) -
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
by: Katrijn Broos, et al.
Published: (2019-06-01) -
Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging
by: Jessica Bridoux, et al.
Published: (2020-04-01) -
Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs
by: Ainhoa Moliner-Morro, et al.
Published: (2020-12-01) -
Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
by: Katty Zeven, et al.
Published: (2023-09-01)